OverviewSuggest Edit

Tanvex Biopharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. It offers biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis.

TypePublic
Founded2013
HQNew Taipei City, TW
Websitetanvex.com

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2021)148(-6%)
Revenue (FY, 2020)NT$300 K
Share Price (Sept 2021)NT$44
Cybersecurity ratingBMore

Key People/Management at Tanvex Biopharma

Chen Lin-Cheng

Chen Lin-Cheng

Chairman, CEO, CFO
Allen Chao

Allen Chao

Founder, Honorary Chairman of the Board of Directors
David Hsia

David Hsia

Director
Yun Yen

Yun Yen

Director
Lee Chiou Chang

Lee Chiou Chang

Independent Director
Jin Pau Tsai

Jin Pau Tsai

Independent Director
Show more

Tanvex Biopharma Office Locations

Tanvex Biopharma has offices in New Taipei City, Taipei City, Irvine and San Diego
New Taipei City, TW (HQ)
33F., No.99, Sec. 1, Xintai 5th Rd., Xizhi Dist.
Taipei City, TW (HQ)
13F.-1, No.376, Sec. 4, Ren’ai Rd., Da’an Dist.
Irvine, CA, US
2030 Main Street #600
San Diego, CA, US
10394 Pacific Center Ct
San Diego, CA, US
10421 Pacific Center Ct #100
Show all (5)

Tanvex Biopharma Financials and Metrics

Tanvex Biopharma Revenue

Tanvex Biopharma's revenue was reported to be NT$300 k in FY, 2020
TWD

Net income (Q1, 2021)

(415.2m)

EBIT (Q1, 2021)

(413.7m)

Market capitalization (17-Sept-2021)

13.7b

Closing stock price (17-Sept-2021)

44.0

Cash (31-Mar-2021)

1.6b

EV

13.5b
Tanvex Biopharma's current market capitalization is NT$13.7 b.
Annual
TWDFY, 2018FY, 2019FY, 2020

Revenue

300.0k

Cost of goods sold

157.0k

Gross profit

143.0k

Gross profit Margin, %

48%
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

300.0k

Cost of goods sold

157.0k

Gross profit

143.0k

Gross profit Margin, %

48%
Annual
TWDFY, 2018FY, 2019FY, 2020

Cash

1.6b2.4b2.1b

Prepaid Expenses

126.2m124.0m142.9m

Inventories

28.6m52.2m50.1m

Current Assets

3.7b2.6b2.3b
Quarterly
TWDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

1.1b1.3b1.0b1.9b1.4b771.8m1.6b

Prepaid Expenses

162.3m159.9m136.9m151.5m115.0m154.1m97.7m

Inventories

44.6m47.5m62.5m57.9m51.7m49.7m52.1m

Current Assets

3.3b2.8b2.2b2.1b1.6b1.0b1.8b
Annual
TWDFY, 2018FY, 2019FY, 2020

Net Income

(1.9b)(2.3b)(2.1b)

Depreciation and Amortization

142.8m216.0m220.4m

Inventories

(28.6m)(23.6m)2.1m

Accounts Payable

(1.4m)
Quarterly
TWDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Depreciation and Amortization

53.8m107.3m161.9m53.4m104.3m159.6m60.3m

Inventories

(16.0m)(18.9m)(33.9m)(5.7m)465.0k2.5m(2.0m)

Cash From Operating Activities

(475.2m)(934.1m)(1.5b)(560.8m)(1.0b)(1.4b)(409.4m)

Purchases of PP&E

(25.3m)(41.8m)(62.7m)(4.3m)(25.8m)(47.4m)(9.4m)
TWDFY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Tanvex Biopharma Operating Metrics

FY, 2018FY, 2019FY, 2020

Facility Space (US), sq. ft.

109 k109 k135 k
Show all operating metrics

Tanvex Biopharma Acquisitions / Subsidiaries

Company NameDateDeal Size
La Jolla Biologics Inc.September 30, 2014
Tanvex Biologics CorporationSeptember 30, 2013
Tanvex BioPharma USA, Inc.

Tanvex Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Tanvex Biopharma Online and Social Media Presence

Embed Graph

Tanvex Biopharma News and Updates

Tanvex entering into service contract with OBI

Tanvex BioPharma announces that it has entered into a service contract with OBI Pharma for the development of a novel antibody drug. Tanvex will be responsible for the cell line development and will leverage its expertise on ensuring the robustness of the cell-line for manufacturing. “With the esta…

FDA delayed inspection for TX01

Tanvex BioPharma announced that it received a complete response letter (CRL) from United States Food and Drug Administration (FDA) in response to the Biologics License Application (BLA) for TX01, a proposed biosimilar to Neupogen® (filgrastim). FDA decided on TX01 BLA that manufacturing site insp…

Tanvex Biopharma Frequently Asked Questions

  • When was Tanvex Biopharma founded?

    Tanvex Biopharma was founded in 2013.

  • Who are Tanvex Biopharma key executives?

    Tanvex Biopharma's key executives are Chen Lin-Cheng, Allen Chao and David Hsia.

  • How many employees does Tanvex Biopharma have?

    Tanvex Biopharma has 148 employees.

  • What is Tanvex Biopharma revenue?

    Latest Tanvex Biopharma annual revenue is NT$300 k.

  • What is Tanvex Biopharma revenue per employee?

    Latest Tanvex Biopharma revenue per employee is NT$2 k.

  • Who are Tanvex Biopharma competitors?

    Competitors of Tanvex Biopharma include OBI Pharma, PharmaEssentia and Bora Pharmaceuticals.

  • Where is Tanvex Biopharma headquarters?

    Tanvex Biopharma headquarters is located at 33F., No.99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City.

  • Where are Tanvex Biopharma offices?

    Tanvex Biopharma has offices in New Taipei City, Taipei City, Irvine and San Diego.

  • How many offices does Tanvex Biopharma have?

    Tanvex Biopharma has 5 offices.